Subject and method: The uncontrolled clinical intervention was conducted on 41 stage III-IVA nasopharyngeal carcinoma patients (with N3 accounting for 46.3%) who underwent induction chemotherapy with 3 cycles of gemcitabin 1000mg / m2 on day 1 and 8 plus cisplatin 80mg / m2 on day 1, followed by concurrent radiotherapy with weekly cisplatin 40mg / m2 from March 2020 to February 2023 at the 108 Military Central Hospital.